If you need more lookups,
subscriptions start at $34 USD/month.
Bernd Schlereth Location
Feusisberg, SZ, CH
Bernd Schlereth Work
2021 -now Chief Development Officer at Araris Biotech AG @
2019 -2021 Vice President Oncology Reasearch @
2013 -2019 Senior Director Nonclinical Development @ Covagen AG and Janssen Pharmaceuticals
2008 -2013 Associate Director global project support nonclinical safety @
2002 -2008 Senior Director Pharmacology and Toxicology @
2000 -2002 Senior Scientist @
Bernd Schlereth Education
University of Surrey
Master of Science (MSc) in applied toxicology (Toxicology)
2003-2007
The Julius Maximilians University of Würzburg
Doctor of Philosophy (Ph.D.) Immunology
1997-2000
The Julius Maximilians University of Würzburg
Diploma in Microbiology
1993-1997
Bernd Schlereth Skills
Drug Development
Non-clinical Development
Primary pharmacology
Safety Pharmacology
DMPK
Toxicology
Regulatory Affairs
Drug Safety
Biopharmaceuticals
Biosimilars
Oncology
Immunology
Autoimmune Diseases
GLP
CRO
Drug Discovery
Clinical Development
Biologics
Vaccines
Life Sciences
Cancer
Pharmacology
Pre-clinical Studies
Training
Strategic Planning
Non Clinical Development
Pre Clinical Studies
Public Speaking
Molecular Biology
Leadership
Customer Service
Management
Project Management
Chemistry
Research
Bernd Schlereth Summary
Bernd Schlereth, based in Feusisberg, SZ, CH, is currently a Chief Development Officer at Araris Biotech AG at Araris Biotech AG. Bernd Schlereth brings experience from previous roles at Molecular Partners AG, Zurich, Switzerland, Covagen AG and Janssen Pharmaceuticals, Merck Group and Micromet AG. Bernd Schlereth holds a 2003 - 2007 Master of Science (MSc) in applied toxicology in Toxicology @ University of Surrey. With a robust skill set that includes Drug Development, Non-clinical Development, Primary pharmacology, Safety Pharmacology, DMPK and more. Bernd Schlereth has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Bernd Schlereth?
Find contact details for 700 million professionals.